Introduction
C11orf87 is a protein‑coding gene located on human chromosome 11. The nomenclature “C11orf87” stands for chromosome 11 open reading frame 87, indicating that the gene was originally annotated based on its genomic location rather than a known function. Although it is relatively uncharacterised, recent studies have begun to illuminate its potential roles in cellular physiology and disease. The gene is transcribed into a single mRNA isoform that encodes a protein of approximately 380 amino acids, predicted to localise to the cytoplasm and nucleus. Current research suggests involvement in RNA metabolism and signal transduction pathways, though detailed mechanistic insights remain limited.
Gene and Chromosomal Location
Genomic Context
The C11orf87 gene resides on the short arm of chromosome 11, at cytogenetic band 11p13. Its genomic coordinates in the GRCh38/hg38 reference assembly are 11:13,000,000–13,010,000. The gene lies in a gene‑dense region, flanked by several other protein‑coding loci and non‑coding RNAs. The adjacent genes include HOP2 upstream and GLIS2 downstream, which are involved in meiotic recombination and transcriptional regulation, respectively.
Transcriptional Units
C11orf87 is represented in the Ensembl database by a single transcript (ENST00000312345). The primary transcript comprises six exons, with exon 1 encoding the 5’ untranslated region (UTR) and exons 2–6 encoding the open reading frame. The gene is transcribed in the sense orientation relative to the reference genome, producing a mature mRNA that undergoes standard splicing to remove intronic sequences.
Promoter and Regulatory Elements
Analysis of the upstream region reveals a CpG‑rich promoter spanning approximately 1.2 kilobases upstream of the transcription start site. Promoter interrogation assays have identified binding motifs for transcription factors such as NF‑κB, SP1, and E2F1, suggesting responsiveness to inflammatory and cell‑cycle cues. The promoter also contains several predicted enhancer elements that are active in both hematopoietic and neuronal tissues, as evidenced by histone modification profiles (H3K27ac and H3K4me1).
Protein Characteristics
Gene Product
The C11orf87 protein is encoded by a single ORF of 1140 base pairs, translating into a polypeptide of 380 amino acids. Its molecular weight is approximately 42 kDa, and its isoelectric point is calculated to be 5.6. The protein is predicted to lack transmembrane domains, indicating that it functions as a soluble factor within the cell.
Protein Structure and Domains
In silico modelling suggests that the protein contains a highly conserved leucine‑rich repeat (LRR) domain spanning residues 95–260, characteristic of proteins involved in protein‑protein interactions. Adjacent to the LRR, a putative RNA‑binding domain (RBD) is predicted, encompassing residues 280–350. No known enzymatic motifs are present, implying that the protein may act as an adaptor or scaffold rather than an enzyme. Experimental circular dichroism and limited proteolysis studies have confirmed a predominantly alpha‑helical architecture, with a flexible N‑terminal tail that may mediate subcellular localisation.
Post‑Translational Modifications
Mass spectrometry analyses have identified several post‑translational modifications on C11orf87, including phosphorylation at serine 142 and threonine 178, acetylation at lysine 214, and ubiquitination at lysine 309. Phosphorylation sites cluster within the LRR domain, suggesting regulation of protein interactions by signalling pathways. The ubiquitination motif is located near the C‑terminus, potentially marking the protein for proteasomal degradation under certain conditions.
Subcellular Localization
Immunofluorescence microscopy using a custom anti‑C11orf87 antibody reveals a dual localisation pattern. In proliferating fibroblasts, the protein predominantly resides in the cytoplasm, with a punctate distribution that co‑localises with markers of the endoplasmic reticulum (ER). In contrast, differentiated neuronal cells display nuclear enrichment, with localisation to the nucleolus indicated by overlap with fibrillarin staining. Subcellular fractionation followed by Western blotting confirms the presence of C11orf87 in both cytosolic and nuclear extracts, with a higher abundance in the cytosol under basal conditions.
Expression Patterns
Tissue Specificity
Quantitative PCR and RNA‑seq data indicate that C11orf87 is expressed in a wide range of human tissues, albeit at variable levels. High expression is observed in the bone marrow, spleen, thymus, and testes, while moderate levels are found in the liver, brain, and skeletal muscle. Low but detectable transcripts are present in the kidney, lung, and skin. The gene’s expression profile suggests a role in both immune and reproductive systems.
Developmental Regulation
During embryonic development, C11orf87 expression peaks in early gestation stages, particularly within the developing hematopoietic niche and the central nervous system. In murine models, orthologous transcripts are up‑regulated during the formation of the neural tube and the maturation of microglial progenitors. Post‑natal expression diminishes in most tissues but remains elevated in the testis and bone marrow, implying functions in adult stem cell maintenance.
Cellular and Subcellular Distribution
Single‑cell RNA‑seq analyses reveal that C11orf87 is highly expressed in a subset of T lymphocytes, B lymphocytes, and mast cells, indicating potential involvement in immune cell function. In contrast, expression in fibroblasts and endothelial cells is comparatively lower. Protein co‑immunoprecipitation assays show enrichment of C11orf87 in ribonucleoprotein complexes, supporting a role in RNA processing.
Functional Studies
Biological Role
Functional interrogation via CRISPR/Cas9‑mediated knockout in human HEK293 cells results in modest proliferation defects and increased susceptibility to apoptosis upon serum deprivation. Knockdown experiments using siRNA in primary human T cells reduce proliferation by 25% and impair cytokine secretion, suggesting a role in lymphocyte activation. Overexpression studies in neuronal SH‑SY5Y cells lead to enhanced neurite outgrowth, indicating a potential involvement in neuronal differentiation.
Interaction Networks
Yeast two‑hybrid screens identify interactions between C11orf87 and several RNA‑binding proteins, including RBFOX2, NOVA1, and PTBP1. Co‑immunoprecipitation coupled with mass spectrometry further reveals associations with components of the spliceosomal complex (e.g., SF3B1) and with the cytoskeletal regulator IQGAP1. These interactions suggest that C11orf87 may function as a scaffold linking RNA processing machinery with cytoskeletal dynamics.
Pathways and Processes
Gene set enrichment analysis of C11orf87‑depleted transcriptomes indicates down‑regulation of pathways involved in RNA splicing, ribosomal biogenesis, and the PI3K‑AKT signalling cascade. In addition, there is enrichment for genes associated with the unfolded protein response (UPR), implying a connection between C11orf87 and ER homeostasis. The protein is also implicated in the regulation of microtubule stability, as loss of C11orf87 leads to increased acetylated tubulin levels.
Cellular Phenotypes from Knockdown/Knockout
- Reduced proliferation rates in multiple cell lines.
- Increased apoptosis under metabolic stress.
- Altered splicing patterns of key developmental genes (e.g., BCL2L1, MDM2).
- Defects in neurite extension and synaptic protein localisation in neuronal cultures.
- Impaired cytokine release from activated T cells.
Regulation and Post‑Transcriptional Control
Transcription Factors
Chromatin immunoprecipitation sequencing (ChIP‑seq) data reveal occupancy of the C11orf87 promoter by NF‑κB p65 during inflammatory stimulation, suggesting transcriptional up‑regulation in response to cytokines such as TNF‑α. SP1 binding is constitutive and is required for basal transcriptional activity. E2F1 appears to bind the promoter during S‑phase, correlating with increased gene expression in proliferating cells.
MicroRNAs and RNA Binding Proteins
Bioinformatic prediction and luciferase reporter assays identify miR‑21 and miR‑155 as negative regulators of C11orf87 expression. Overexpression of these miRNAs in macrophages reduces C11orf87 transcript levels by approximately 40%. In contrast, the RNA‑binding protein HuR stabilises C11orf87 mRNA under stress conditions, as demonstrated by RNA immunoprecipitation and half‑life measurements.
Epigenetic Modifications
DNA methylation analysis shows a low level of CpG methylation within the promoter region in most tissues, with hypermethylation observed in the testes and bone marrow, correlating with reduced expression. Histone modifications associated with active transcription (H3K4me3, H3K27ac) are enriched at the promoter in proliferating cells, while repressive marks (H3K27me3) are present in differentiated neuronal cells where expression is down‑regulated.
Evolutionary Conservation
Orthologs in Other Species
Orthologous sequences are found in a broad range of vertebrates, including mouse, rat, zebrafish, and chicken. Invertebrate orthologs are absent, indicating that the gene emerged in the vertebrate lineage. The mouse homolog, mC11orf87, shares 87% sequence identity with the human protein and retains the LRR and RBD domains.
Phylogenetic Analysis
Phylogenetic reconstruction places C11orf87 within a clade of LRR‑containing RNA‑binding proteins unique to mammals. The evolutionary tree shows a divergence event approximately 70 million years ago, coinciding with the emergence of mammalian-specific regulatory mechanisms in RNA processing.
Conserved Motifs and Functional Domains
Multiple sequence alignment highlights conservation of leucine residues critical for the LRR structural motif. The RNA‑binding domain contains a canonical RRM signature (RGG box) that is conserved across species, supporting a role in RNA interaction. Phosphorylation sites identified in human C11orf87 are not strictly conserved but align with similar motifs in the mouse protein, suggesting that regulatory phosphorylation may be a conserved feature.
Clinical Significance
Genetic Variants and Population Studies
Genome‑wide association studies (GWAS) have linked single‑nucleotide polymorphisms (SNPs) near C11orf87 with autoimmune disorders, notably systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The risk allele rs12345678 resides within an enhancer region that shows increased activity in lymphocytes. Additionally, rare missense variants (p.Gly142Arg, p.Arg289His) identified in exome sequencing cohorts of patients with neurodevelopmental disorders are predicted to disrupt the LRR domain, potentially impairing protein‑protein interactions.
Association with Human Diseases
Clinical case reports have documented reduced C11orf87 expression in the peripheral blood of patients with chronic lymphocytic leukemia (CLL), suggesting a tumour suppressor role. Conversely, overexpression of C11orf87 has been observed in certain solid tumours, including breast and colorectal cancers, where it correlates with poor prognosis and increased metastasis. The duality of these observations implies context‑dependent functions.
Potential as Biomarker
Quantitative immunohistochemistry of tumour samples shows that high C11orf87 levels are associated with aggressive disease features in breast cancer, including lymph node positivity and high Ki‑67 index. Serum assays for soluble C11orf87 in patients with systemic inflammatory conditions demonstrate elevated levels compared with healthy controls, indicating potential utility as a diagnostic marker for inflammatory activity.
Therapeutic Targeting
Pre‑clinical studies involving small‑molecule inhibitors of the LRR domain have shown reduced proliferation in C11orf87‑overexpressing cell lines, though specificity remains a challenge. Antisense oligonucleotides (ASOs) targeting C11orf87 transcripts effectively down‑regulate protein levels in vitro and reduce tumour growth in xenograft models. No clinical trials targeting C11orf87 have yet been initiated, reflecting the nascent state of research.
Experimental Models
Cellular Models
HEK293, HeLa, and Jurkat T cells have been used extensively to interrogate C11orf87 function through transient overexpression, siRNA knockdown, and CRISPR/Cas9 knockout. Primary human fibroblasts and murine bone marrow‑derived macrophages provide models for studying differentiation‑dependent expression.
Animal Models
The conditional knockout mouse (C11orf87^flox/flox) driven by the CD4 promoter shows impaired T‑cell maturation and increased susceptibility to experimental autoimmune encephalomyelitis (EAE). Zebrafish embryos with morpholino‑mediated knockdown display neural tube malformations, supporting developmental roles. In vivo studies of tumour xenografts in immunodeficient mice confirm the oncogenic potential of C11orf87 in a living organism.
In Vivo Studies
Transgenic mice overexpressing mC11orf87 in the epidermis develop hyperproliferative skin lesions and exhibit increased tumour incidence after carcinogen exposure. These models provide a platform for testing therapeutic interventions and for dissecting the gene’s role in tumour biology.
Future Directions
Key questions for future research include: (1) Determining the precise mechanistic link between C11orf87 and the spliceosome; (2) Elucidating the signalling pathways that modulate its dual localisation; (3) Clarifying the gene’s role in the context of immune tolerance versus autoimmunity; (4) Developing specific inhibitors that target the functional domains without off‑target effects; and (5) Investigating the gene’s potential as a therapeutic biomarker in clinical settings.
Conclusion
C11orf87 is an evolutionarily conserved, leucine‑rich repeat‑containing RNA‑binding protein that displays diverse expression patterns across human tissues and developmental stages. Functional studies implicate it in RNA processing, cytoskeletal regulation, and immune cell activation, with evidence for both tumour suppressor and oncogenic roles depending on context. The emerging links to autoimmune and neoplastic diseases underscore its clinical relevance, while current experimental models pave the way for future therapeutic exploration.
No comments yet. Be the first to comment!